Efficacy and Safety of DLBS1033 in Subjects With Type 2 Diabetes Mellitus
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 4
Locations
Indonesia
Study Type
Interventional
Intervention
DLBS1033
placebo tablet of DLBS1033
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring DLBS1033, Type 2 DM, fibrinolytic, hypercoagulation
Eligibility Criteria
Inclusion Criteria:
- Diagnosed as type 2 diabetes mellitus with A1c > 7.0% at Screening.
- Men or women, between 25-65 years of age.
- Have been being treated with lifestyle intervention and/or any oral anti-diabetic agents and/or insulin.
- Adequate liver function: ALT and AST ≤ 2.5 times upper limit of normal.
- Adequate renal function: serum creatinine < 2.0 times upper limit of normal.
- Able to take oral medication.
Exclusion Criteria:
For females of childbearing potential: Pregnancy, breast-feeding, the intention of becoming pregnant.
- Patients must accept pregnancy tests during the trial if menstrual cycle is missed.
- Fertile patients must use a reliable and effective contraceptive.
- The presence of clinically significant electrocardiographic abnormality
- History of acute coronary syndrome (myocardial infarction, stroke, unstable angina pectoris), peripheral arterial diseases, venous thromboembolism or other cardiovascular events.
- History of other arteriosclerotic disease necessitating medical or pharmacological treatment.
- Severe hypertension (systolic blood pressure ≥ 180 mm Hg, diastolic ≥ 110 mm Hg).
- Treatment with antiplatelets or antithrombotic agents, including other oral lumbrokinase products within 14 days prior to Screening.
- Subjects with prior experience with DLBS1033.
- Subjects with high-risk of bleeding
- Presence of malignancies as observed clinically or by anamnesis.
- Subjects with any other disease state, including chronic or acute systemic infections, or uncontrolled illnesses, which judged by the investigator, could interfere with trial participation or trial evaluation.
- Subjects with known or suspected allergy to study medication or similar products.
- Subjects with concurrent herbal (alternative) medicines or food supplements suspected to have effect on the primary efficacy endpoint.
- Subjects enrolled in another experimental (interventional) protocol within the past 30 days prior to Screening.
Sites / Locations
- Department of Internal Medicine, Faculty of Medicine, University of Andalas/ dr. M. Djamil Padang Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Treatment I
Treatment II
Arm Description
DLBS1033 bioactive fraction tablet 490 mg thrice daily
Placebo tablet of DLBS1033, thrice daily
Outcomes
Primary Outcome Measures
Fibrinogen level reduction
Fibrinogen level reduction from baseline to the end of study (Week 8th)
Secondary Outcome Measures
Change of D-dimer
Change of D-dimer from baseline to every follow-up visit
Change of von Willebrand Factor activity
Change of von Willebrand Factor activity from baseline to every follow-up visit.
Change of hs-CRP level
Change of hs-CRP level from baseline to every follow-up visit.
Change of HbA1c
Change of HbA1c from baseline to end of study (Week 8th).
Liver function
Liver function (serum ALT, AST,γ-glutamyl transferase, alkaline phosphatase) at baseline and end of study (Week 8th)
Renal function
Renal function (serum creatinine, BUN) at baseline and end of study (Week 8th)
Prothrombin Time (PT)
Prothrombin time from baseline to every follow-up visit
Activated partial thromboplastin time (aPTT)
Activated partial thromboplastin time (aPTT)from baseline to every follow-up visit
Adverse events
Adverse events (mainly: GI bleeding, and other bleeding events) from baseline to every follow-up visit
Change of Thromboxane-B2 level
Change of Thromboxane-B2 level from baseline to every follow-up visit (as an indirect indicator to assess the effect of study treatment on TxA2)
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01865474
Brief Title
Efficacy and Safety of DLBS1033 in Subjects With Type 2 Diabetes Mellitus
Official Title
DLBS1033 Therapy in Improving Hypercoagulation State in Subjects With Type 2 Diabetes Mellitus
Study Type
Interventional
2. Study Status
Record Verification Date
August 2016
Overall Recruitment Status
Completed
Study Start Date
May 2013 (undefined)
Primary Completion Date
June 2016 (Actual)
Study Completion Date
June 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Dexa Medica Group
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a prospective, double-blind, randomized, and controlled study. The investigational product, DLBS1033 at a dose of 490 mg thrice daily or placebo, will be given for an 8-week course of therapy.
DLBS1033 effectively demonstrated fibrinolytic, fibrinogenolytic as well as antithrombotic activities. Hypercoagulation state with high fibrinogen level is usually found in diabetes mellitus patients.
Therefore, the hypothesis of interest of this study is that DLBS1033 will reduce fibrinogen level of diabetes mellitus patients better than that of the Control Group.
Detailed Description
There will be 2 groups of treatment, each consisting of 68 subjects, with the treatment regimens as the following:
Treatment I : DLBS1033 bioactive fraction tablet @ 490 mg, three times daily. Treatment II : Placebo tablet of DLBS1033, three times daily.
Clinical examination to evaluate the efficacy of the investigational drug will be performed at baseline and every follow-up visit (at interval of 4 weeks) over the 8 weeks of study period. All subjects will be advised to follow such a lifestyle modification throughout the study period.
All subjects will be under direct supervision of a medical doctor during the study period.
During the study period, anti-diabetes treatment taken by study subjects should still be continued. Other treatment related to subjects' concomitant illnesses, such as hypertension, and/or dyslipidemia, is allowed during subjects' participation in the study.
Other medication such as anti-platelets, fibrinolytic agents and anti-coagulants, or other treatment including herbals/alternatives which may affect haemostatic system, are not allowed to be used during the study period.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
DLBS1033, Type 2 DM, fibrinolytic, hypercoagulation
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
122 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Treatment I
Arm Type
Experimental
Arm Description
DLBS1033 bioactive fraction tablet 490 mg thrice daily
Arm Title
Treatment II
Arm Type
Experimental
Arm Description
Placebo tablet of DLBS1033, thrice daily
Intervention Type
Drug
Intervention Name(s)
DLBS1033
Other Intervention Name(s)
Disolf
Intervention Description
1 DLBS1033 tablet 490 mg thrice daily for 2 months
Intervention Type
Drug
Intervention Name(s)
placebo tablet of DLBS1033
Other Intervention Name(s)
placebo tablet of Disolf
Intervention Description
1 placebo tablet of DLBS1033 thrice daily for 2 months
Primary Outcome Measure Information:
Title
Fibrinogen level reduction
Description
Fibrinogen level reduction from baseline to the end of study (Week 8th)
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
Change of D-dimer
Description
Change of D-dimer from baseline to every follow-up visit
Time Frame
4 weeks and 8 weeks
Title
Change of von Willebrand Factor activity
Description
Change of von Willebrand Factor activity from baseline to every follow-up visit.
Time Frame
4 weeks and 8 weeks
Title
Change of hs-CRP level
Description
Change of hs-CRP level from baseline to every follow-up visit.
Time Frame
4 weeks and 8 weeks
Title
Change of HbA1c
Description
Change of HbA1c from baseline to end of study (Week 8th).
Time Frame
8 weeks
Title
Liver function
Description
Liver function (serum ALT, AST,γ-glutamyl transferase, alkaline phosphatase) at baseline and end of study (Week 8th)
Time Frame
8 weeks
Title
Renal function
Description
Renal function (serum creatinine, BUN) at baseline and end of study (Week 8th)
Time Frame
8 weeks
Title
Prothrombin Time (PT)
Description
Prothrombin time from baseline to every follow-up visit
Time Frame
4 weeks and 8 weeks
Title
Activated partial thromboplastin time (aPTT)
Description
Activated partial thromboplastin time (aPTT)from baseline to every follow-up visit
Time Frame
4 weeks and 8 weeks
Title
Adverse events
Description
Adverse events (mainly: GI bleeding, and other bleeding events) from baseline to every follow-up visit
Time Frame
4 weeks and 8 weeks (during 8 weeks)
Title
Change of Thromboxane-B2 level
Description
Change of Thromboxane-B2 level from baseline to every follow-up visit (as an indirect indicator to assess the effect of study treatment on TxA2)
Time Frame
4 weeks and 8 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosed as type 2 diabetes mellitus with A1c > 7.0% at Screening.
Men or women, between 25-65 years of age.
Have been being treated with lifestyle intervention and/or any oral anti-diabetic agents and/or insulin.
Adequate liver function: ALT and AST ≤ 2.5 times upper limit of normal.
Adequate renal function: serum creatinine < 2.0 times upper limit of normal.
Able to take oral medication.
Exclusion Criteria:
For females of childbearing potential: Pregnancy, breast-feeding, the intention of becoming pregnant.
Patients must accept pregnancy tests during the trial if menstrual cycle is missed.
Fertile patients must use a reliable and effective contraceptive.
The presence of clinically significant electrocardiographic abnormality
History of acute coronary syndrome (myocardial infarction, stroke, unstable angina pectoris), peripheral arterial diseases, venous thromboembolism or other cardiovascular events.
History of other arteriosclerotic disease necessitating medical or pharmacological treatment.
Severe hypertension (systolic blood pressure ≥ 180 mm Hg, diastolic ≥ 110 mm Hg).
Treatment with antiplatelets or antithrombotic agents, including other oral lumbrokinase products within 14 days prior to Screening.
Subjects with prior experience with DLBS1033.
Subjects with high-risk of bleeding
Presence of malignancies as observed clinically or by anamnesis.
Subjects with any other disease state, including chronic or acute systemic infections, or uncontrolled illnesses, which judged by the investigator, could interfere with trial participation or trial evaluation.
Subjects with known or suspected allergy to study medication or similar products.
Subjects with concurrent herbal (alternative) medicines or food supplements suspected to have effect on the primary efficacy endpoint.
Subjects enrolled in another experimental (interventional) protocol within the past 30 days prior to Screening.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Asman Manaf, Prof. Dr. dr., SpPD-KEMD
Organizational Affiliation
Department of Internal Medicine, Faculty of Medicine, University of Andalas/ dr. M. Djamil Padang Hospital, Padang, Sumatera Barat, Indonesia
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Internal Medicine, Faculty of Medicine, University of Andalas/ dr. M. Djamil Padang Hospital
City
Padang
State/Province
Sumatera Barat
Country
Indonesia
12. IPD Sharing Statement
Learn more about this trial
Efficacy and Safety of DLBS1033 in Subjects With Type 2 Diabetes Mellitus
We'll reach out to this number within 24 hrs